Tags

Type your tag names separated by a space and hit enter

Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) confirms that abaloparatide is a valuable addition to the armamentarium against osteoporosis.
Expert Opin Pharmacother. 2017 Dec; 18(17):1811-1813.EO

Abstract

The recently published Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) assessed the efficacy and safety of abaloparatide (80 µg daily subcutaneous) (ABL) vs placebo during 18 months, in postmenopausal osteoporosis. Teriparatide (20 µg daily subcutaneous) (TPD) was used as an open label active comparator. The results of the study suggest that ABL increases bone mineral density more than TPD and reduces major osteoporotic fractures to a greater extent than TPD with a more rapid onset of action. These outcomes combined with a positive safety profile make ABL an interesting addition to the armamentarium against postmenopausal osteoporosis.

Authors+Show Affiliations

a Public Health, Epidemiology and Health Economics , University of Liège , Liège , Belgium. b WHO Collaborating Center for Public Health Aspects of Musculoskeletal Health and Aging , Liège , Belgium.b WHO Collaborating Center for Public Health Aspects of Musculoskeletal Health and Aging , Liège , Belgium. c Biochemistry Department, College of Science , King Saud University , Riyadh , Saudi Arabia.a Public Health, Epidemiology and Health Economics , University of Liège , Liège , Belgium. b WHO Collaborating Center for Public Health Aspects of Musculoskeletal Health and Aging , Liège , Belgium.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

29048260

Citation

Reginster, Jean-Yves, et al. "Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) Confirms That Abaloparatide Is a Valuable Addition to the Armamentarium Against Osteoporosis." Expert Opinion On Pharmacotherapy, vol. 18, no. 17, 2017, pp. 1811-1813.
Reginster JY, Al Daghri NM, Bruyere O. Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) confirms that abaloparatide is a valuable addition to the armamentarium against osteoporosis. Expert Opin Pharmacother. 2017;18(17):1811-1813.
Reginster, J. Y., Al Daghri, N. M., & Bruyere, O. (2017). Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) confirms that abaloparatide is a valuable addition to the armamentarium against osteoporosis. Expert Opinion On Pharmacotherapy, 18(17), 1811-1813. https://doi.org/10.1080/14656566.2017.1395021
Reginster JY, Al Daghri NM, Bruyere O. Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) Confirms That Abaloparatide Is a Valuable Addition to the Armamentarium Against Osteoporosis. Expert Opin Pharmacother. 2017;18(17):1811-1813. PubMed PMID: 29048260.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) confirms that abaloparatide is a valuable addition to the armamentarium against osteoporosis. AU - Reginster,Jean-Yves, AU - Al Daghri,Nasser Mohammad, AU - Bruyere,Olivier, Y1 - 2017/11/14/ PY - 2017/10/20/pubmed PY - 2018/1/26/medline PY - 2017/10/20/entrez KW - Abaloparatide KW - anabolic agents KW - fracture KW - hypercalcemia KW - osteoporosis KW - parathyroid hormone KW - teriparatide SP - 1811 EP - 1813 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 18 IS - 17 N2 - The recently published Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) assessed the efficacy and safety of abaloparatide (80 µg daily subcutaneous) (ABL) vs placebo during 18 months, in postmenopausal osteoporosis. Teriparatide (20 µg daily subcutaneous) (TPD) was used as an open label active comparator. The results of the study suggest that ABL increases bone mineral density more than TPD and reduces major osteoporotic fractures to a greater extent than TPD with a more rapid onset of action. These outcomes combined with a positive safety profile make ABL an interesting addition to the armamentarium against postmenopausal osteoporosis. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/29048260/Abaloparatide_Comparator_Trial_In_Vertebral_Endpoints__ACTIVE__confirms_that_abaloparatide_is_a_valuable_addition_to_the_armamentarium_against_osteoporosis_ L2 - https://www.tandfonline.com/doi/full/10.1080/14656566.2017.1395021 DB - PRIME DP - Unbound Medicine ER -